SK280584B6 - Spôsob prípravy arylpiperazinylových heterocyklick - Google Patents

Spôsob prípravy arylpiperazinylových heterocyklick Download PDF

Info

Publication number
SK280584B6
SK280584B6 SK485-93A SK48593A SK280584B6 SK 280584 B6 SK280584 B6 SK 280584B6 SK 48593 A SK48593 A SK 48593A SK 280584 B6 SK280584 B6 SK 280584B6
Authority
SK
Slovakia
Prior art keywords
group
compound
formula
chloro
neutralizing agent
Prior art date
Application number
SK485-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK48593A3 (en
Inventor
Frank Robert Busch
Paul Bouwles
Douglas J. M. Allen
Sabeto A. Diroma
Dennis M. Godek
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25468285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK280584(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK48593A3 publication Critical patent/SK48593A3/sk
Publication of SK280584B6 publication Critical patent/SK280584B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lubricants (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Eye Examination Apparatus (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cephalosporin Compounds (AREA)
SK485-93A 1992-08-26 1993-05-14 Spôsob prípravy arylpiperazinylových heterocyklick SK280584B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/936,179 US5206366A (en) 1992-08-26 1992-08-26 Process for preparing aryl piperazinyl-heterocyclic compounds

Publications (2)

Publication Number Publication Date
SK48593A3 SK48593A3 (en) 1994-04-06
SK280584B6 true SK280584B6 (sk) 2000-04-10

Family

ID=25468285

Family Applications (1)

Application Number Title Priority Date Filing Date
SK485-93A SK280584B6 (sk) 1992-08-26 1993-05-14 Spôsob prípravy arylpiperazinylových heterocyklick

Country Status (27)

Country Link
US (1) US5206366A (no)
EP (2) EP1029861B1 (no)
JP (1) JP2742370B2 (no)
KR (1) KR0123441B1 (no)
CN (1) CN1033089C (no)
AT (2) ATE206422T1 (no)
AU (1) AU642836B1 (no)
BR (1) BR9302065A (no)
CZ (1) CZ281893B6 (no)
DE (2) DE69330853T2 (no)
DK (2) DK0584903T3 (no)
EG (1) EG20214A (no)
ES (2) ES2225015T3 (no)
FI (1) FI111641B (no)
HU (1) HU223312B1 (no)
IL (1) IL105622A (no)
MX (1) MX9302813A (no)
MY (1) MY109731A (no)
NO (1) NO300685B1 (no)
NZ (1) NZ247539A (no)
PL (1) PL173840B1 (no)
PT (2) PT1029861E (no)
RU (1) RU2061695C1 (no)
SI (1) SI9300287A (no)
SK (1) SK280584B6 (no)
YU (1) YU48964B (no)
ZA (1) ZA936225B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
AU697953B2 (en) * 1995-06-06 1998-10-22 Hoechst Marion Roussel, Inc. Benzisoxazole and indazole derivatives as antipsychotic agents
SI0904273T1 (en) * 1996-05-07 2003-08-31 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
US5945421A (en) * 1997-08-11 1999-08-31 Warner-Lambert Company Dopamine D4 receptor antagonists
US6040448A (en) * 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
BR9908510A (pt) * 1998-03-06 2000-11-21 Astrazeneca Ab Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6660858B2 (en) 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
OA12923A (en) * 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
WO2004037819A1 (en) * 2002-10-24 2004-05-06 Pfizer Products Inc. Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity
WO2004041793A1 (en) * 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
ITMI20040944A1 (it) * 2004-05-11 2004-08-11 Dinamite Dipharma S P A In For Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006011157A2 (en) * 2004-06-18 2006-02-02 Lupin Limited Methods for the preparation of aryl piperazinyl-heterocyclic compounds
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
AU2006228426A1 (en) * 2005-04-01 2006-10-05 Warner-Lambert Company Llc Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
HU230479B1 (hu) * 2006-05-02 2016-07-28 Richter Gedeon Nyrt. Eljárás 5-{2-[4-(1,2-benzizotiazol-3-il)-1-piperazinil]-etil}-6-klór-1,3-dihidro-2H-indol-2-on (Ziprasidon) előállítására
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
WO2009116085A2 (en) * 2008-03-11 2009-09-24 Alkem Laboratories Ltd. An improved process for the preparation of ziprasidone
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
PL391810A1 (pl) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
WO2012020424A1 (en) 2010-08-12 2012-02-16 Arch Pharmalabs Limited A short process for the preparation of ziprasidone and intermediates thereof
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610988A (en) * 1982-04-09 1986-09-09 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines useful for alleviating pain
FR2536749A1 (fr) * 1982-11-25 1984-06-01 Cerm Cent Europ Rech Mauvernay (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride

Also Published As

Publication number Publication date
CZ281893B6 (cs) 1997-03-12
RU2061695C1 (ru) 1996-06-10
NO931656L (no) 1994-02-28
FI932012A0 (fi) 1993-05-04
NO931656D0 (no) 1993-05-06
EP1029861A1 (en) 2000-08-23
DK1029861T3 (da) 2004-11-15
SK48593A3 (en) 1994-04-06
YU56593A (sh) 1996-07-24
MX9302813A (es) 1994-02-28
DE69330853D1 (de) 2001-11-08
EG20214A (en) 1997-11-30
NO300685B1 (no) 1997-07-07
ES2161703T3 (es) 2001-12-16
EP1029861B1 (en) 2004-08-18
FI111641B (fi) 2003-08-29
SI9300287A (en) 1994-03-31
PL173840B1 (pl) 1998-05-29
EP0584903A1 (en) 1994-03-02
ES2225015T3 (es) 2005-03-16
PL299002A1 (en) 1994-03-21
PT584903E (pt) 2002-02-28
CN1083061A (zh) 1994-03-02
JPH06184143A (ja) 1994-07-05
BR9302065A (pt) 1994-07-26
ZA936225B (en) 1995-02-27
IL105622A (en) 1998-06-15
HU9301291D0 (en) 1993-07-28
IL105622A0 (en) 1993-09-22
EP0584903B1 (en) 2001-10-04
NZ247539A (en) 1995-09-26
HU223312B1 (hu) 2004-05-28
DE69330853T2 (de) 2002-05-02
HUT65750A (en) 1994-07-28
PT1029861E (pt) 2004-11-30
DE69333597T2 (de) 2005-09-15
YU48964B (sh) 2003-01-31
US5206366A (en) 1993-04-27
KR940003952A (ko) 1994-03-14
CN1033089C (zh) 1996-10-23
CZ87793A3 (en) 1994-04-13
ATE273976T1 (de) 2004-09-15
FI932012A (fi) 1994-02-27
JP2742370B2 (ja) 1998-04-22
DE69333597D1 (de) 2004-09-23
MY109731A (en) 1997-05-31
ATE206422T1 (de) 2001-10-15
DK0584903T3 (da) 2001-12-03
KR0123441B1 (ko) 1997-11-24
AU642836B1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
SK280584B6 (sk) Spôsob prípravy arylpiperazinylových heterocyklick
CA2095587C (en) Process for preparing aryl piperazinyl-hetero-cyclic compounds
US7381737B2 (en) Crystalline forms and process for preparing spiro-hydantoin compounds
US9512096B2 (en) Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
AU2003257300B2 (en) Amino benzothiazole compounds with NOS inhibitory activity
FR2510572A1 (fr) Nouvelles thiazolidinediones, leur procede de production et preparation pharmaceutique les contenant
US20060142319A1 (en) Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7186727B2 (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
CN111518104B (zh) 一种含硫脲嘧啶的1,2,4-三氮唑并[1,5-a]嘧啶类化合物及其制备方法和应用
NL8203035A (nl) Spirothiazolidinylpiperazinederivaten.
KR20000051515A (ko) 항바이러스 활성을 가지는 2-아미노퓨린

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20090514